• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Merck Kgaa (OP: MKGAF )

    167.54 +3.64 (+2.22%)
    Streaming Delayed Price Updated: 2:26 PM EDT, Jun 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 100
    Open 166.98
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 163.90
    Today's Range 166.98 - 167.80
    52wk Range 143.46 - 193.63
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis
    Merck KGaA (OTC: MKGAF) (OTC:  
    Via Benzinga
    Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7 Billion
    Jiangsu Hengrui Pharma out-licensed global rights for its next-gen PARP1 inhibitor to Germany’s Merck KGaA for a $170 million upfront payment and up to $1.5 billion in milestones. Merck will have... 
    Via Talk Markets

    Performance

    YTD
    +8.44%
    +8.44%
    1 Month
    -8.19%
    -8.19%
    3 Month
    -5.24%
    -5.24%
    6 Month
    +4.75%
    +4.75%
    1 Year
    +1.85%
    +1.85%

    More News

    Read More
    Life Sciences Player Repligen's Strategic European Acquisition - What It Means for Investors
    Via Benzinga
    Merck Germany Reports 5% Decline In Q2 Sales, Expects More Decline In 2023
    Via Benzinga
    Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List
    Via Benzinga
    Abcam Downgrade: Analyst Trims Expectations Amid Activist Investor Engagement and Potential Bid Anticipation
    Via Benzinga
    Roche's Investigational Drug For Relapsing Multiple Sclerosis Reduces Brain Lesions, Data Shows
    Via Benzinga
    Analyst Says Nektar Therapeutics' Rezpeg Prioritization Likely to Spark Investor Questions
    Via Benzinga
    FDA Issues Partial Clinical Hold On Merck Germany's Multiple Sclerosis Study
    Via Benzinga
    Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer
    Via Benzinga
    Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval
    Via Benzinga
    PDS Biotech, Merck Germany Enter Licensing Pact For Investigational Cancer Treatment
    Via Benzinga
    Mersana Inks Cancer Therapy Development Deal With Merck Germany
    Via Benzinga
    GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact
    Via Benzinga
    Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study
    Via Benzinga
    Merck KGaA Pulls Plug On GSK-Partnered Cancer Drug Trial
    Via Benzinga
    Sutro Biopharma Receives Undisclosed Milestone Payment Under Bispecific ADC Collaboration with Merck
    Via Benzinga
    Immutep, Merck Germany Team Up for Eftilagimod/Bintrafusp Combo Trial In Solid Tumors
    Via Benzinga
    Gene Therapy Player Vera Therapeutics Prices IPO Well Below Range At $11/Share
    Via Benzinga
    Topics Initial Public Offering
    Exposures Securities Market
    UK's NICE Provisionally Rejects Coverage Of Pfizer-Merck KGaA's Bavencio As First-Line Therapy For Bladder Cancer
    Via Benzinga
    Palantir Deepens Relationship With Ringier To Help It Transform Into A Digital-First, Global Media Company
    Via Benzinga
    Novartis Taps Artios In Discovery Pact To Enhance Radioligand Portfolio
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.